The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지
DOI QR코드

DOI QR Code

Current Status of Translational Research on Irritable Bowel Syndrome

과민성장증후군과 연관된 중개연구 현황

  • Kwon, Yong Hwan (Department of Internal Medicine, Kyungpook National University School of Medicine) ;
  • Kim, Hyun Jin (Department of Internal Medicine, Gyeongsang National University School of Medicine)
  • 권용환 (경북대학교 의학전문대학원 내과학교실) ;
  • 김현진 (경상대학교 의학전문대학원 내과학교실)
  • Published : 2016.09.01
⟨ Previous Next ⟩

Abstract

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. The pathophysiology of IBS is not completely understood. Genetic, immune, environmental, inflammatory, neurological and psychological factors contribute to the risk of this condition. Traditional research explored gastrointestinal motor abnormalities, central neural dysregulation, abnormal psychological features, and visceral hypersensitivity. More recent investigations consider bacterial overgrowth, abnormal serotonin pathways, altered gut flora, immune activation and mucosal inflammation. The purpose of this article is to review recent translational research concerning the pathophysiology, biomarker and genetic factors of IBS and to encourage IBS research in Korea.

Keywords

References

  1. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-1580. https://doi.org/10.1007/BF01303162
  2. Lee SY, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion 2009;79:196-201. https://doi.org/10.1159/000211715
  3. Park DW, Lee OY, Shim SG, et al. The differences in prevalence and sociodemographic characteristics of irritable bowel syndrome according to Rome II and Rome III. J Neurogastroenterol Motil 2010;16:186-193. https://doi.org/10.5056/jnm.2010.16.2.186
  4. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002;16:1171-1185. https://doi.org/10.1046/j.1365-2036.2002.01290.x
  5. Lu CL, Chang FY, Lang HC, Chen CY, Luo JC, Lee SD. Gender difference on the symptoms, health-seeking behaviour, social impact and sleep quality in irritable bowel syndrome: a Rome II-based survey in an apparent healthy adult Chinese population in Taiwan. Aliment Pharmacol Ther 2005;21:1497-1505. https://doi.org/10.1111/j.1365-2036.2005.02512.x
  6. Rey E, Garcia-Alonso MO, Moreno-Ortega M, Alvarez-Sanchez A, Diaz-Rubio M. Determinants of quality of life in irritable bowel syndrome. J Clin Gastroenterol 2008;42:1003-1009. https://doi.org/10.1097/MCG.0b013e31815af9f1
  7. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016. doi: 10.1053/j.gastro.2016.02.032. [Epub ahead of print]
  8. Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014. https://doi.org/10.1038/nrdp.2016.14
  9. Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol 2014;14:189. https://doi.org/10.1186/s12876-014-0189-7
  10. Martinez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 2013;62:1160-1168. https://doi.org/10.1136/gutjnl-2012-302093
  11. Fritscher-Ravens A, Schuppan D, Ellrichmann M, et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 2014;147:1012-1020.e4. https://doi.org/10.1053/j.gastro.2014.07.046
  12. Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 2011;17:349-359. https://doi.org/10.5056/jnm.2011.17.4.349
  13. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702. https://doi.org/10.1053/j.gastro.2003.11.055
  14. Nasser Y, Boeckxstaens GE, Wouters MM, Schemann M, Vanner S. Using human intestinal biopsies to study the pathogenesis of irritable bowel syndrome. Neurogastroenterol Motil 2014;26:455-469. https://doi.org/10.1111/nmo.12316
  15. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26-37. https://doi.org/10.1053/j.gastro.2006.11.039
  16. Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636-647. https://doi.org/10.1172/JCI29255
  17. Annahazi A, Gecse K, Dabek M, et al. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. Pain 2009;144:209-217. https://doi.org/10.1016/j.pain.2009.04.017
  18. Annahazi A, Ferrier L, Bezirard V, et al. Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS. Am J Gastroenterol 2013;108:1322-1331. https://doi.org/10.1038/ajg.2013.152
  19. Buhner S, Braak B, Li Q, et al. Neuronal activation by mucosal biopsy supernatants from irritable bowel syndrome patients is linked to visceral sensitivity. Exp Physiol 2014;99:1299-1311. https://doi.org/10.1113/expphysiol.2014.080036
  20. Valdez-Morales EE, Overington J, Guerrero-Alba R, et al. Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2. Am J Gastroenterol 2013;108:1634-1643. https://doi.org/10.1038/ajg.2013.241
  21. Cenac N, Bautzova T, Le Faouder P, et al. Quantification and potential functions of endogenous agonists of transient receptor potential channels in patients with irritable bowel syndrome. Gastroenterology 2015;149:433-444.e7. https://doi.org/10.1053/j.gastro.2015.04.011
  22. Dothel G, Barbaro MR, Boudin H, et al. Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 2015;148:1002-1011.e4. https://doi.org/10.1053/j.gastro.2015.01.042
  23. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013;145:1262-1270.e1. https://doi.org/10.1053/j.gastro.2013.08.048
  24. Sood R, Law GR, Ford AC. Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'? Nat Rev Gastroenterol Hepatol 2014;11:683-691. https://doi.org/10.1038/nrgastro.2014.127
  25. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012;367:1626-1635. https://doi.org/10.1056/NEJMra1207068
  26. Mujagic Z, Ludidi S, Keszthelyi D, et al. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. Aliment Pharmacol Ther 2014;40:288-297. https://doi.org/10.1111/apt.12829
  27. Sood R, Gracie DJ, Law GR, Ford AC. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther 2015;42:491-503. https://doi.org/10.1111/apt.13283
  28. Sood R, Ford AC. Combining biomarkers in irritable bowel syndrome: a forward step toward making a positive diagnosis and directing therapy? Gastroenterology 2015;148:1471-1473. https://doi.org/10.1053/j.gastro.2015.04.032
  29. Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr 2008;27:328-339. https://doi.org/10.1016/j.clnu.2008.02.005
  30. Windmueller HG, Spaeth AE. Source and fate of circulating citrulline. Am J Physiol 1981;241:E473-E480.
  31. Lutgens LC, Blijlevens NM, Deutz NE, Donnelly JP, Lambin P, de Pauw BE. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer 2005;103:191-199. https://doi.org/10.1002/cncr.20733
  32. Bashashati M, Rezaei N, Shafieyoun A, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and metaanalysis. Neurogastroenterol Motil 2014;26:1036-1048. https://doi.org/10.1111/nmo.12358
  33. Lembo AJ, Neri B, Tolley J, Barken D, Carroll S, Pan H. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009;29:834-842. https://doi.org/10.1111/j.1365-2036.2009.03975.x
  34. Jones MP, Chey WD, Singh S, et al. A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther 2014;39:426-437. https://doi.org/10.1111/apt.12608
  35. van Vliet MJ, Tissing WJ, Rings EH, et al. Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients. Pediatr Blood Cancer 2009;53:1188-1194. https://doi.org/10.1002/pbc.22210
  36. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551. https://doi.org/10.1053/j.gastro.2004.11.050
  37. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615-621. https://doi.org/10.1111/j.1365-2036.2004.02128.x
  38. Ohman L, Stridsberg M, Isaksson S, Jerlstad P, Simren M. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol 2012;107:440-447. https://doi.org/10.1038/ajg.2011.458
  39. Vora P, Youdim A, Thomas LS, et al. Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol 2004;173:5398-5405. https://doi.org/10.4049/jimmunol.173.9.5398
  40. Langhorst J, Junge A, Rueffer A, et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009;104:404-410. https://doi.org/10.1038/ajg.2008.86
  41. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:512-519, e114-e115.
  42. Facer P, Bishop AE, Lloyd RV, Wilson BS, Hennessy RJ, Polak JM. Chromogranin: a newly recognized marker for endocrine cells of the human gastrointestinal tract. Gastroenterology 1985;89:1366-1373. https://doi.org/10.1016/0016-5085(85)90657-2
  43. Ford AC, Talley NJ. IBS in 2010: advances in pathophysiology, diagnosis and treatment. Nat Rev Gastroenterol Hepatol 2011;8:76-78. https://doi.org/10.1038/nrgastro.2010.216
  44. Saito YA, Petersen GM, Larson JJ, et al. Familial aggregation of irritable bowel syndrome: a family case-control study. Am J Gastroenterol 2010;105:833-841. https://doi.org/10.1038/ajg.2010.116
  45. Bengtson MB, Ronning T, Vatn MH, Harris JR. Irritable bowel syndrome in twins: genes and environment. Gut 2006;55:1754-1759. https://doi.org/10.1136/gut.2006.097287
  46. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510-2516. https://doi.org/10.1111/j.1572-0241.2005.00257.x
  47. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531. https://doi.org/10.1126/science.274.5292.1527
  48. Pata C, Erdal ME, Derici E, Yazar A, Kanik A, Ulu O. Serotonin transporter gene polymorphism in irritable bowel syndrome. Am J Gastroenterol 2002;97:1780-1784. https://doi.org/10.1111/j.1572-0241.2002.05841.x
  49. Van Kerkhoven LA, Laheij RJ, Jansen JB. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:979-986. https://doi.org/10.1111/j.1365-2036.2007.03453.x
  50. Kim HJ, Camilleri M, Carlson PJ, et al. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004;53:829-837. https://doi.org/10.1136/gut.2003.030882
  51. Andresen V, Camilleri M, Kim HJ, et al. Is there an association between GNbeta3-C825T genotype and lower functional gastrointestinal disorders? Gastroenterology 2006;130:1985-1994. https://doi.org/10.1053/j.gastro.2006.03.017
  52. Saito YA, Locke GR 3rd, Zimmerman JM, et al. A genetic association study of 5-HTT LPR and GNbeta3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterol Motil 2007;19:465-470. https://doi.org/10.1111/j.1365-2982.2007.00905.x
  53. Gazouli M, Wouters MM, Kapur-Pojskic L, et al. Lessons learned--resolving the enigma of genetic factors in IBS. Nat Rev Gastroenterol Hepatol 2016;13:77-87. https://doi.org/10.1038/nrgastro.2015.206
  54. Beyder A, Mazzone A, Strege PR, et al. Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome. Gastroenterology 2014;146:1659-1668. https://doi.org/10.1053/j.gastro.2014.02.054
  55. Camilleri M, Carlson P, Valentin N, et al. Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea. Am J Physiol Gastrointest Liver Physiol 2016. doi: 10.1152/ajpgi.00037.2016. [Epub ahead of print]

Cited by

  1. 설사형 과민성대장증후군 환자에 대한 저령차전자탕의 효과 2례 vol.40, pp.5, 2016, https://doi.org/10.22246/jikm.2019.40.5.948